Literature DB >> 11896487

Impaired glucose metabolism in the heart of obese Zucker rats after treatment with phorbol ester.

D Morabito1, C Montessuit, N Rosenblatt-Velin, R Lerch, M B Vallotton, U Lang.   

Abstract

OBJECTIVE: To investigate the influence of obesity on the regulation of myocardial glucose metabolism following protein kinase C (PKC) activation in obese (fa/fa) and lean (Fa/?) Zucker rats.
DESIGN: Isolated hearts obtained from 17-week-old lean and obese Zucker rats were perfused with 200 nM phorbol 12-myristate 13-acetate (PMA) for different time periods prior to the evaluation of PKC and GLUT-4 translocation. For metabolic studies isolated hearts from 48 h starved Zucker rats were perfused with an erythrocytes-enriched buffer containing increased concentrations (10-100 nM) of PMA. MEASUREMENTS: Immunodetectable PKC isozymes and GLUT-4 were determined by Western blots. Glucose oxidation and glycolysis were evaluated by measuring the myocardial release of 14CO2 and 3H2O from [U-14C]glucose and [5-3H]glucose, respectively.
RESULTS: PMA (200 nM) induced maximal translocation of ventricular PKCalpha from the cytosol to the membranes within 10 min. This translocation was 2-fold lower in the heart from obese rats when compared to lean rats. PMA also induced a significant translocation of ventricular GLUT-4 from the microsomal to the sarcolemmal fraction within 60 min in lean but not in obese rats. Rates of basal cardiac glucose oxidation and glycolysis in obese rats were approximately 2-fold lower than those of lean rats. Perfusion with increasing concentrations of PMA (10-100 nM) led to a significant decrease of cardiac glucose oxidation in lean but not in obese rats.
CONCLUSION: Our results show that in the heart of the genetically obese Zucker rat, the impairment in PKCalpha activation is in line with a diminished activation of GLUT-4 as well as with the lack of PMA effect on glucose oxidation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896487     DOI: 10.1038/sj.ijo.0801881

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  3 in total

1.  Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts.

Authors:  L N Axelsen; W Keung; H D Pedersen; E Meier; D Riber; A L Kjølbye; J S Petersen; S D Proctor; N-H Holstein-Rathlou; G D Lopaschuk
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Regulation of skeletal muscle oxidative capacity and insulin signaling by the mitochondrial rhomboid protease PARL.

Authors:  Anthony E Civitarese; Paul S MacLean; Stacy Carling; Lyndal Kerr-Bayles; Ryan P McMillan; Anson Pierce; Thomas C Becker; Cedric Moro; Jean Finlayson; Natalie Lefort; Christopher B Newgard; Lawrence Mandarino; William Cefalu; Ken Walder; Greg R Collier; Matthew W Hulver; Steven R Smith; Eric Ravussin
Journal:  Cell Metab       Date:  2010-05-05       Impact factor: 27.287

3.  Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts.

Authors:  Vanlata Patel; Raghu Adya; Jing Chen; Manjunath Ramanjaneya; Muhammad F Bari; Sunil K Bhudia; Edward W Hillhouse; Bee K Tan; Harpal S Randeva
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.